tiprankstipranks
Blurbs

H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals (AUPHResearch Report), with a price target of $26.00. The company’s shares opened today at $7.58.

According to TipRanks, Arce is a 4-star analyst with an average return of 7.6% and a 39.28% success rate. Arce covers the Healthcare sector, focusing on stocks such as Assembly Biosciences, Cidara Therapeutics, and Pliant Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aurinia Pharmaceuticals with a $17.90 average price target.

See today’s best-performing stocks on TipRanks >>

AUPH market cap is currently $1.08B and has a P/E ratio of -6.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles